Traditional Chinese medicine （TCM） is commonly used in treating liver diseases worldwide, especially in China. The advantages of using TCM for treatment of liver diseases include： protecting hepatocytes, inhibiting...Traditional Chinese medicine （TCM） is commonly used in treating liver diseases worldwide, especially in China. The advantages of using TCM for treatment of liver diseases include： protecting hepatocytes, inhibiting hepatic inflammation and antifibrosis in the liver. In this article, we introduce TCM herbal preparations from the Chinese materia medica （such as Fuzheng Huayu） that are typically used for the treatment of liver diseases. Literature surrounding the mechanisms of TCM therapy for treatment of liver diseases is presented and discussed. We propose that side effects of herbal compounds are often under-appreciated, and that more care should be taken in the prescription of potentially hepatotoxic medicines. Further, to deepen the understanding of TCM mechanisms, new techniques and methodologies must be developed. Future studies will lead to the enhancement of clinical outcomes of TCM. As complementary and alternative therapies, TCMs will play an expanding role in the future of liver disease treatment.展开更多
目的:通过对西安医学院附属医院肝炎患者保肝药使用的调查和分析,探讨西安医学院附属医院保肝药在临床的使用情况及其合理性.方法:采用药物利用评价(drug utilization review,DUR)和药物利用评估(drug utilization evaluation,DUE)法,...目的:通过对西安医学院附属医院肝炎患者保肝药使用的调查和分析,探讨西安医学院附属医院保肝药在临床的使用情况及其合理性.方法:采用药物利用评价(drug utilization review,DUR)和药物利用评估(drug utilization evaluation,DUE)法,对西安医学院附属医院肝炎住院患者的药物利用指数(drug use index,DUI)、用药情况、治疗过程监测和治疗结果进行统计分析.结果:129例肝炎患者中,DUI>1的药物为2种,DUI<1的药物为2种,DUI=1的药物为5种,分别占保肝药调查品种的22.2%、22.2%和55.6%;用药频度占前3位的药物分别为水飞蓟宾胶囊、注射用还原型谷胱甘肽、多烯磷脂酰胆碱注射液,其频度分别为52.78%、21.23%和21.04%;一联、二联、三联和四联联合用药患者的构成比分别为15.5%、48.1%、34.9%和1.6%;肝功恢复正常或好转的患者中,分别归属于一联、二联、三联和四联用药的患者比例为55%、96.8%、86.7%和50%.经四格表资料的F i s h e r确切概率法检验,四种联用方式有显著性差异(P<0.01),疗效强弱依次为二联、三联、一联和四联.结论:西安医学院附属医院肝炎患者的用药基本合理,二联用药的保肝治疗效果最好.展开更多
基金supported by the National Basic Research Program(973 Program)of China(No.2006CB504800)National Natural Science Foundation of China(No.30271657 and No.30672489)+3 种基金Leading Academic Discipline Project of Shanghai Municipal Education Commission(No.J50307)Innovation Research Team in Universities,Shanghai Municipal Education CommissionLeading Academic Discipline of Hepatology of State Administration of TCM China(No.2010sh)Three-year Action Plan of Shanghai TCM Development(No.ZYSNXD-CC-YJXYY)
文摘Traditional Chinese medicine （TCM） is commonly used in treating liver diseases worldwide, especially in China. The advantages of using TCM for treatment of liver diseases include： protecting hepatocytes, inhibiting hepatic inflammation and antifibrosis in the liver. In this article, we introduce TCM herbal preparations from the Chinese materia medica （such as Fuzheng Huayu） that are typically used for the treatment of liver diseases. Literature surrounding the mechanisms of TCM therapy for treatment of liver diseases is presented and discussed. We propose that side effects of herbal compounds are often under-appreciated, and that more care should be taken in the prescription of potentially hepatotoxic medicines. Further, to deepen the understanding of TCM mechanisms, new techniques and methodologies must be developed. Future studies will lead to the enhancement of clinical outcomes of TCM. As complementary and alternative therapies, TCMs will play an expanding role in the future of liver disease treatment.
文摘目的:通过对西安医学院附属医院肝炎患者保肝药使用的调查和分析,探讨西安医学院附属医院保肝药在临床的使用情况及其合理性.方法:采用药物利用评价(drug utilization review,DUR)和药物利用评估(drug utilization evaluation,DUE)法,对西安医学院附属医院肝炎住院患者的药物利用指数(drug use index,DUI)、用药情况、治疗过程监测和治疗结果进行统计分析.结果:129例肝炎患者中,DUI>1的药物为2种,DUI<1的药物为2种,DUI=1的药物为5种,分别占保肝药调查品种的22.2%、22.2%和55.6%;用药频度占前3位的药物分别为水飞蓟宾胶囊、注射用还原型谷胱甘肽、多烯磷脂酰胆碱注射液,其频度分别为52.78%、21.23%和21.04%;一联、二联、三联和四联联合用药患者的构成比分别为15.5%、48.1%、34.9%和1.6%;肝功恢复正常或好转的患者中,分别归属于一联、二联、三联和四联用药的患者比例为55%、96.8%、86.7%和50%.经四格表资料的F i s h e r确切概率法检验,四种联用方式有显著性差异(P<0.01),疗效强弱依次为二联、三联、一联和四联.结论:西安医学院附属医院肝炎患者的用药基本合理,二联用药的保肝治疗效果最好.
